With approximately 25 percent of people with HIV who are in care relying Medicare for coverage, the implementation of Medicare Part D drug coverage in 2006 was an important improvement to the program for people with HIV.
With approximately 25 percent of people with HIV who are in care relying Medicare for coverage, the implementation of Medicare Part D drug coverage in 2006 was an important improvement to the program for people with HIV.
Giving states a new option to impose new restrictions on some program beneficiaries would represent a setback to essential health service access, and add a new challenge to the Ending the HIV Epidemic initiative.
The Infectious Diseases Society of America and its HIV Medicine Association endorse the measures to control the spread of COVID-19 called for by the Trump administration Monday.
The Infectious Diseases Society of America and its HIV Medicine Association welcome President-elect Biden’s selection of Dr. Rochelle Walensky to lead the U.S. Centers for Disease Control and Prevention.
Address serious concerns regarding the impact of the proposed rule to expand the benefits considered under a “public charge” determination. We urge the Department of Homeland Security to rescind the proposed rule due to the harm it would have on the health of immigrants, their families including children, and on public health.
Our members provide medical care and treatment to people living with HIV in the U.S. and globally, lead HIV prevention programs and conduct research that has led to the development of effective HIV prevention and treatment options
More than 500 physicians, health care providers and researchers urge Presidential candidates to prioritize ID and HIV responses.
HHS is proposing to significantly narrow the ACA’s non-discrimination protections. Take action to urge protections for LGBTQ people and patients with HIV are maintained.
IDSA has awarded 23 institutions the designation of Antimicrobial Stewardship Centers of Excellence (CoE).
Dr. Collins has provided a steady, scientific voice throughout the COVID-19 pandemic. Under his leadership, NIH was instrumental in researching, developing and communicating about lifesaving COVID-19 vaccines and treatments.
The update to the 2019 recommendation retains the Grade A rating following a review of the latest evidence for PrEP, including for new long-acting formulations.